apl. Prof. Dr. Jürgen Rech

Einrichtungen, die zum Universitätsklinikum Erlangen gehören Medizinische Fakultät Department of Medicine 3 – Rheumatology and Immunology

SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS (PSA) THROUGH 3 YEARS: EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL (2017) Hall S, Mease P, Kavanaugh A, Reimold A, Tahir H, Rech J, Geusens P, et al. Conference contribution Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 2-year efficacy and safety results from the phase 3 randomised, double-blind, placebo-controlled trial FUTURE 1 (2017) Rech J, Reinhardt M, Kavanaugh A, Geusens P, Mpofu S Conference contribution MULTI-BIOMARKER DISEASE ACTIVITY (MBDA) IS ASSOCIATED WITH THE PROGRESSION OF STRUCTURAL BONE DAMAGE IN RHEUMATOID ARTHRITIS PATIENTS IN REMISSION (2017) Schett G, Finzel S, Hagen M, Englbrecht M, Haschka J, Figuereido C, Cobra JF, Rech J Conference contribution OPTIMAL DOSE OF TOCILIZUMAB FOR THE TREATMENT OF GIANT CELL ARTERITIS: EFFICACY, SAFETY, AND EXPOSURE-EFFICACY ANALYSIS FROM GIACTA (2017) Stone JH, Tuckwell K, Dimonaco S, Klearman M, Mallalieu NL, Aringer M, Blockmans D, et al. Conference contribution OPEN-LABEL, MULTICENTER, DOSE-ESCALATING PHASE II CLINICAL TRIAL ON THE SAFETY AND EFFICACY OF TADEKINIG ALPHA IN ADULT ONSET STILL'S DISEASE (2017) Gabay C, Fautrel B, Rech J, Spertini F, Feist E, Koetter I, Hachulla E, et al. Conference contribution QUANTITATIVE ASSESSMENT AND ANALYSIS OF HAND MUSCLE VOLUME (2017) Friedberger A, Figueiredo C, Museyko O, Grimm A, D'Oliveira I, Bäuerle T, Rech J, et al. Conference contribution IL-17-22-23 PATHWAYS IN PSORIATIC ARTHRITIS AND PSORIASIS (2017) Nas K, Cevik R, Yildiz I, Rech J, Schett G Conference contribution CORTICAL BONE LOSS IS AN EARLY FEATURE OF AXIAL SPONDYLOARTHRITIS (2017) Haschka J, Neumann A, Kleyer A, Schuster L, Englbrecht M, Figueiredo CP, Muschitz C, et al. Conference contribution PREVALENCE AND CHARACTERISTICS OF SPONDYLOARTHRITIS ACCORDING TO ASAS CRITERIA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE - RESULTS FROM THE SPICE COHORT (2017) Haschka J, Hirschmann S, Kleyer A, Englbrecht M, Zimmermann J, Faustini F, Simon D, et al. Conference contribution Prediction of Response to Certolizumab-Pegol in Rheumatoid Arthritis By Functional MRI of the Brain - an Interim Analysis of an Ongoing Investigator Initiated Phase III Trial (2017) Schenker H, Heß A, Konerth L, Sergeeva M, Prade J, Kleyer A, Reiser M, et al. Conference contribution